{"url":"https://newsforagent.com/news/2026-10-21/merck-enpatoran-phase-3-lupus-first-dose","markdown_url":"https://newsforagent.com/news/2026-10-21/merck-enpatoran-phase-3-lupus-first-dose.md","title":"Merck Doses First Patient in Phase 3 Lupus Skin Trial","headline":"Merck Begins Phase 3 Enpatoran Program With First Lupus Patient Dosed","description":"Merck dosed the first patient in its Phase 3 ELOWEN-1 and ELOWEN-2 studies of enpatoran, recruiting about 200 lupus participants at each of 266 sites.","section":"Research & Clinical Trials","published_at":"2026-10-21T22:03:31+00:00","modified_at":"2026-10-21T22:03:31+00:00","author":"News Desk","key_takeaways":["Merck announced the first patient was dosed in the Phase 3 ELOWEN-1 and ELOWEN-2 studies of enpatoran in lupus patients with active skin manifestations.","Each study will recruit approximately 200 participants across 266 sites in 26 countries, with change in CLASI-A from baseline as the primary endpoint.","Enpatoran is an investigational oral selective TLR7/8 inhibitor and has not been approved for any use anywhere in the world."],"companies":[{"name":"Merck","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00009dg/merck","website":"https://www.merckgroup.com"}],"source":{"publisher":"Business Wire","title":"Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations","url":"https://www.businesswire.com/news/home/20260430733656/en/"},"other_sources":[],"tags":["Research & Clinical Trials","Merck"],"body_markdown":"[Merck](https://akta.pro/company-profiles/00009dg/merck) announced the first patient was dosed in the Phase 3 program ELOWEN-1 and ELOWEN-2, evaluating enpatoran in people living with lupus who experience active skin manifestations. The studies will recruit about 200 participants each across 266 sites in 26 countries, with the primary endpoint being change in CLASI-A from baseline, [Business Wire](https://www.businesswire.com/news/home/20260430733656/en/) reported.\n\n## Inside the ELOWEN-1 and ELOWEN-2 Studies\n\nELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218) are two global randomized, double-blind, placebo-controlled Phase 3 studies evaluating enpatoran taken twice daily versus placebo, on top of standard of care, in patients with lupus who have active cutaneous manifestations. Each study will recruit approximately 200 lupus participants, and the primary endpoint will be a change in CLASI-A from baseline.\n\nEnpatoran is an investigational, oral, selective inhibitor of toll-like receptors 7 and 8 (TLR7/8), which play a key role in immune pathways involved in lupus. The company said enpatoran has the potential to be the first targeted therapy for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards of care for patients with CLE and SLE. Enpatoran is currently under clinical investigation and has not been approved for any use anywhere in the world.\n\n\"People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,\" said David Weinreich, Global Head of R&D, Merck. \"With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.\"\n\nProfessor Eric Morand, principal investigator, said the ELOWEN program builds on Phase 2 findings, where enpatoran demonstrated clinically meaningful improvements in patients with active cutaneous manifestations, regardless of their underlying lupus diagnosis.\n\n## Merck's Recent Deal and Leadership Moves\n\nMerck is a Darmstadt-based science and technology company with more than 62,000 employees across 65 countries, according to akta.pro [company records](https://akta.pro/company-data). The same records list a March 2026 partnership with Quotient Therapeutics, a multi-year collaboration using Quotient's somatic genomics platform for inflammatory bowel disease drug discovery, under which Merck will pay $20 million upfront with Quotient eligible for more than $2 billion in development, regulatory, and commercial milestones.\n\n## Earlier Merck KGaA Developments\n\nBloomberg reported on October 19, 2026, that Merck KGaA agreed to acquire Silence Therapeutics for about $1.1 billion in cash, paying $20 per American depositary receipt, a 130% premium to Friday's close, with the deal expected to close in the first quarter of 2027. FierceBiotech reported on October 13, 2026, that iOnctura's roginolisib, a PI3K delta inhibitor, showed promise in a phase 1 study of 44 patients with advanced solid and hematologic malignancies, including metastatic uveal melanoma.\n\n## What Comes Next for the ELOWEN Program\n\nThe Silence Therapeutics acquisition is expected to close in the first quarter of 2027, according to Bloomberg.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}